Nuformix (LON:NFX) Stock Price Down 24% – Here’s Why

Nuformix plc (LON:NFX) shares traded down 24% during mid-day trading on Thursday . The stock traded as low as GBX 0.21 and last traded at GBX 0.23. 394,899,813 shares were traded during mid-day trading, an increase of 787% from the average session volume of 44,533,070 shares. The stock had previously closed at GBX 0.30.

Nuformix Stock Performance

The company has a market cap of £4.43 million, a PE ratio of -5.34 and a beta of 1.41. The stock’s 50 day moving average price is GBX 0.26 and its 200-day moving average price is GBX 0.24.

Nuformix (LON:NFX) last issued its earnings results on Tuesday, January 27th. The company reported GBX (0.04) earnings per share for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.